Turner Jenkins
About Turner Jenkins
Turner Jenkins serves as the Executive Director of Alliance Strategy and Management at Mirati Therapeutics, bringing extensive experience in corporate development within the biopharmaceutical industry. He holds a BS in Chemical Engineering from UCLA and an MBA from UC San Diego's Rady School of Management.
Current Role at Mirati Therapeutics
Turner Jenkins serves as the Executive Director of Alliance Strategy and Management at Mirati Therapeutics. He has held this position since 2020, contributing to the company's strategic initiatives in the biopharmaceutical sector. His role involves overseeing the development and management of alliances that support Mirati's mission in advancing targeted therapies for cancer.
Previous Experience in Corporate Development
Prior to his current role, Turner Jenkins worked in various capacities within corporate development. He was the Senior Director and Head of Corporate Development at Regulus Therapeutics from 2017 to 2019. Before that, he served as Senior Director of Corporate Development at Otonomy, Inc. from 2014 to 2017. His experience in these roles focused on strategic planning and partnership development within the biopharmaceutical industry.
Educational Background
Turner Jenkins holds a Bachelor of Science degree in Chemical Engineering with a Biomedical Option from the University of California, Los Angeles. He furthered his education by obtaining a Master of Business Administration (MBA) in Entrepreneurial and Small Business Operations from the University of California, San Diego - The Rady School of Management. His educational background supports his expertise in the biopharmaceutical field.
Skills and Expertise
Turner Jenkins possesses a strong skill set in valuation and financial modeling, particularly in the context of company formation and market research. He has significant expertise in arranging strategic alliances within the biopharmaceutical industry. Additionally, he has a solid background in technology evaluation and due diligence, which enhances his contributions to corporate development and strategic management.
Career Progression and Early Roles
Turner Jenkins began his career as a Staff Scientist at MediVas from 2003 to 2006. He then transitioned to Pappas Ventures, where he served as an Associate from 2008 to 2012. His career also includes a role as Director of Strategic Planning at Sequenom from 2012 to 2014, and as a Corporate Operations Consultant at Amylin Pharmaceuticals from 2007 to 2008. This diverse experience laid the foundation for his current leadership role in alliance strategy.